Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05692830 · ClinicalTrials.gov registry record
Towards a Wearable Alcohol Biosensor: Examining the Accuracy of BAC Estimates From New-Generation Transdermal Technology Using Large-Scale Human Testing and Machine Learning Algorithms
A clinical trial of Alcohol Drinking and Alcohol Intoxication, sponsored by University of Illinois at Urbana-Champaign.
- Recruiting
- Registry status
- 240
- Enrollment target
- 1
- Study location
NCT05692830: Recruiting study of Alcohol Drinking and Alcohol Intoxication, sponsored by University of Illinois at Urbana-Champaign.
NCT05692830 is a study of Alcohol Drinking and Alcohol Intoxication that is actively recruiting participants, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 240 participants, below the 628-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05692830, a study of Alcohol Drinking and Alcohol Intoxication, is actively recruiting participants, sponsored by University of Illinois at Urbana-Champaign.
- RECRUITING
- Registry status
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will employ a combined laboratory-ambulatory design. Participants will engage in ambulatory assessment over the course of 14 days, wearing biosensors assessing transdermal alcohol concentration (TAC) and providing breathalyzer readings in real-world contexts. Also during this period, participants will attend three laboratory alcohol-administration sessions scheduled at one-week intervals, with alcohol dose and rate of consumption manipulated within and between participants, respectively. Laboratory visits will also double as ambulatory orientation, check-in, and close-out sessions.
Primary Outcome
We will assess the accuracy of transdermal estimates of drinking vs sobriety
Conditions Studied
Interventions
- DRUG Alcohol
Study Locations (1)
Illinois
- University of Illinois at Urbana-Champaign - Champaign
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2022-10-22 |
| Est. Completion | 2027-09-01 |
What NCT05692830 shows while recruiting
NCT05692830 is an observational study that tracks outcomes without assigning an intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 628-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Alcohol Drinking appearing as the primary indexed condition, and to 1 intervention - of which Alcohol is the first listed.
NCT05692830 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05692830 about?
NCT05692830 is a clinical study titled "Towards a Wearable Alcohol Biosensor: Examining the Accuracy of BAC Estimates From New-Generation Transdermal Technology Using Large-Scale Human Testing and Machine Learning Algorithms". The study will employ a combined laboratory-ambulatory design. Participants will engage in ambulatory assessment over the course of 14 days, wearing biosensors assessing transdermal alcohol concentration (TAC) and providing breathalyzer readings in real-world contexts. Also during this period, parti...
What is the current status of trial NCT05692830?
This trial is currently recruiting. The enrollment target is 240 participants. The study started on 2022-10-22. Estimated completion is 2027-09-01.
What conditions does trial NCT05692830 study?
This clinical trial studies the following conditions: Alcohol Drinking, Alcohol Intoxication.
What interventions are being tested in trial NCT05692830?
The interventions under investigation include: Alcohol (DRUG).
Who is sponsoring clinical trial NCT05692830?
This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05692830 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Drinking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05692830's enrollment target sits among peer trials
240 38th of 85 higher than 47 of 85 other Alcohol Drinking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Drinking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alcohol and "Heat of the Moment" Sexual Decision Making
RECRUITING · NA
-
Nicotinic Receptor Genetic Variation and Alcohol Reward
RECRUITING · Phase 1
-
Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers
RECRUITING · NA
-
The GLUCID Study: Effect of Alcohol Reduction and Probiotic Interventions on Cognition and Brain Glucose Metabolism in Normal Aging Adults Who Are High-Risk Alcohol Drinkers
RECRUITING · NA
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI